Total plasma tissue factor pathway inhibitor levels in pre-eclampsia

Clinica Chimica Acta

Volumn 388, Issue 1-2, 2008, Pages 230-232

  Dusse, Luci M ^a   Carvalho, Maria G ^a   Getliffe, Kathryn ^b   Voegeli, David ^b   Cooper, Alan J ^c   Lwaleed, Bashir A ^b,d  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AMINO TERMINAL SEQUENCE; BLOOD CLOTTING; BLOOD SAMPLING; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; LETTER; MEDICAL ETHICS; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; SMOKING;

ADULT; FEMALE; HUMANS; LIPOPROTEINS; PRE-ECLAMPSIA; PREGNANCY;

EID: 37249073438     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.10.029     Document Type: Letter

References (27)

1. Butenas S., Bouchart B.A., Brummel-Ziedins K.E., Parhami-Seren B., and Mann K.G. Tissue factor activity in whole blood. Blood 105 (2005) 2764-2770
2. Bombeli T., Mueller M., and Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost 77 (1997) 408-423
3. Villar J., Say L., Gülmezoglu A.M., Merialdi M., Lindheimer M.D., Betrán A.P., et al. Eclampsia and pre-eclampsia a worldwide health problem for 2000 years. In: Critchley H., MacLean A., Poston L., and Walker J. (Eds). Pre-eclampsia (2003), RCOG Press, London 189-207
4. National high blood pressure education program working group report on high pressure in pregnancy. Am J Obstet Gynecol 163 (1990) 1691-1712
5. Arias F., and Mancilla-Jimenez R. Hepatic fibrinogen deposits in pre-eclampsia. Immunofluorescent evidence. N Engl J Med 295 (1976) 578-582
6. Brown M.A. The physiology of preeclampsia. Clin Exp Pharmacol Physiol 22 (1995) 781-791
7. Redmann C.W.G., Sacks G.P., and Sargent I.L. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 180 (1999) 499-506
8. Redmann C.W.G., and Sargent I.L. Pre-eclampsia, the placenta and the maternal systemic inflammatory response-a review. Placenta 24 (2003) S21-S27
9. Roberts J.M., Taylor R.N., Musci T.I., Roggers G.M., Hubel C.A., and Mclaughlin M.K. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 159 (1989) 908-914
10. Dusse L.M., Carvalho M.G., Getliffe K., Voegeli D., Cooper A.J., and Lwaleed B.A. Increased circulating thrombomodulin levels in pre-eclampsia. Clin Chim Acta 387 (2008) 168-171
11. Cheng G., Shan J., Xu G., Liu P., Zhou Y., Zhu Y., et al. Relationship between endothelial dysfunction, oxidant stress and aspirin resistance in patients with stable coronary heart disease. J Clin Pharm Ther 32 (2007) 287-292
12. Cella G., Saetta M., Baraldo S., Turato G., Papi A., Casoni G., et al. Endothelial cell activity in chronic obstructive pulmonary disease without severe pulmonary hypertension. Clin Appl Thromb/Hemost 11 (2005) 435-440
13. Sandset P.M., Hogevold H.E., Lybert T., Andersson T.R., and Abildgaard U. Extrinsic pathway inhibitor in elective surgery: a comparison with other coagulation inhibitors. Thromb. Haemost. 62 (1989) 856-860
14. Schjetlein R., Abdelnoor M., Haugan G., Husby H., Sandset P.M., and Wisloff F. Hemostatic variables as independent predictors for fetal growth retardation in pre-eclampsia. Acta Obstet Gynecol Scand 78 (1999) 191-197
15. Abdel Gader M.A., Al-Mishari A.A., Awadalia S.A., Buyuomi A., Khashoggi T., and Al-Hakeem M. Total and free tissue factor pathway inhibitor in pregnancy hipertension. Int J Gynecol Obstet 95 (2006) 248-253
16. Falciani M., Gori A.M., Fedi S., Chiarugi L., Simonetti I., Dabizzi R.P., et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb. Haemost. 79 (1998) 495-499
17. Freeburn J.C., Wallace J.M., Strain J.J., Sinnamon D.G., Craig B.M., Johnson D., et al. Monocyte tissue factor-like activity in post myocardial infarction patients. Br J Haematol 102 (1998) 605-608
18. Vambergue A., Rugeri L., Gaveriaux V., Devos P., Martin A., Fermon C., et al. Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age. Thromb Res 101 (2001) 367-375
19. Leurs P.B., Stolk R.P., Hamulyak K., Van Oerle R., Grobbee D.E., and Wolffenbuttel B.H. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 25 (2002) 1340-1345
20. Lindahl A.K., Jacobsen P.B., Sandset P.M., and Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis 2 (1991) 713-721
21. Lindahl A.K., Sandset P.M., and Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 3 (1992) 439-449
22. Souto J.C., Martinez E., Roca M., Mateo J., Pujol J., Gonzalez D., et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 40 (1995) 1883-1889
23. Palmier M.O., Hall L.J., Reisch C.M., Baldwin M.K., Wilson A.G., and Wun T.C. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb. Haemost. 68 (1992) 33-36
24. Donahue B.S., Gailani D., and Mast A.E. Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass. J Thromb Haemost 4 (2006) 1011-1016
25. Moran P., Lindheimer M.D., and Davison J.M. The renal response to preeclampsia. Semin Nephrol 24 (2004) 588-595
26. Novotny W.F., Girard T.J., Miletich J.P., and Broze G.J. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 264 (1989) 18832-19937
27. Sandset P.M. Tissue factor pathway inhibitor (TFPI)-an update. Haemostasis 26 (1996) 154-165